Skip to main content
SpringerLink
Log in

Congenital and Acquired Hypercoagulable States

  • Chapter
  • First Online:
Trauma Induced Coagulopathy

  • 1848 Accesses

Abstract

Hypercoagulable states, also called thrombophilia, can be either congenital or acquired. Congenital thrombophilia, associated mainly with venous thrombosis, is secondary either to coagulation-inhibitor deficiencies, i.e., antithrombin, protein C and Protein S, or gain of function mutations, i.e., factor V Leiden and prothrombin G20210A mutations. Despite the relative frequency of these two mutations, they have not been associated with venous thrombosis recurrence. Acquired thrombophilia, is associated with arterial and venous thrombosis, and is mainly due to antiphospholipid syndrome, cancer, or myeloproliferative neoplasms. This chapter gives the clinician guidance on diagnostic and treatment strategies of these conditions. The chapter also provides insights into the pathophysiology of thrombosis related to these pathologic states.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Emmerich J, Aiach M, Morange PE. Thrombophilia genetics. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White II GC, editors. Hemostasis and thrombosis. Basic principles and clinical practice. 6th ed. Philadelphia, PA: Wolters Kluwer, Lippincott Williams & Wilkins; 2012.

    Google Scholar 

  2. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell. 1993;72(4):477–80.

    Article  CAS  PubMed  Google Scholar 

  3. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167–73.

    Article  CAS  PubMed  Google Scholar 

  4. Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3 A structure of dimeric antithrombin. Structure. 1994;2(4):257–70.

    Article  CAS  PubMed  Google Scholar 

  5. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci PM, De Stefano V, Palareti G, Finazzi G, Baudo F, Quintavalla R. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol. 1999;19(4):1026–33.

    Article  CAS  PubMed  Google Scholar 

  6. Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G, Faioni EM. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92(7):2353–8.

    CAS  PubMed  Google Scholar 

  7. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, Gavasso S, Huisman MV, Büller HR, Wouter ten Cate J, Girolami A, Prins MH. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81(2):198–202.

    CAS  PubMed  Google Scholar 

  8. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77(1):197–211.

    CAS  PubMed  Google Scholar 

  9. Picard V, Dautzenberg MD, Villoutreix BO, Orliaguet G, Alhenc-Gelas M, Aiach M. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood. 2003;102(3):919–25.

    Article  CAS  PubMed  Google Scholar 

  10. Molho-Sabatier P, Aiach M, Gaillard I, Fiessinger JN, Fischer AM, Chadeuf G, Clauser E. Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation. J Clin Invest. 1989;84(4):1236–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Esmon CT. The endothelial cell protein C receptor. Thromb Haemost. 2000;83(5):639–43.

    CAS  PubMed  Google Scholar 

  12. Rosing J, Hoekema L, Nicolaes GA, Thomassen MC, Hemker HC, Varadi K, Schwartz HP, Tans G. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270(46):27852–8.

    Article  CAS  PubMed  Google Scholar 

  13. Griffin JH, Gruber A, Fernandez JA. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood. 1992;79(12):3203–11.

    CAS  PubMed  Google Scholar 

  14. Boerger LM, Morris PC, Thurnau GR, Esmon CT, Com PC. Oral contraceptives and gender affect protein S status. Blood. 1987;69(2):692–4.

    CAS  PubMed  Google Scholar 

  15. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbrooke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85(10):2756–61.

    CAS  PubMed  Google Scholar 

  16. Borgel D, Reny JL, Fischelis D, Gandrille S, Emmerich J, Fiessinger JN, Aiach M. Cleaved protein S (PS), total PS, free PS, and activated protein C cofactor activity as risk factors for venous thromboembolism. Clin Chem. 2003;49(4):575–80.

    Article  CAS  PubMed  Google Scholar 

  17. Reitsma PH, Bernardi F, Doig RG, Gandrill S, Greengard JS, Ireland H, Krawczak M, Long GL, Poort SR. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1995;73(5):876–89.

    CAS  PubMed  Google Scholar 

  18. Gandrille S, Borgel D, Ireland H, Lane DA, Simmonds R, Reitsma PH, Mannhalter C, Pabinger I, Saito H, Suzuki K, Formstone C, Cooper DA, Espinosa Y, Sala N, Bernardi F, Aiach M. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77(6):1201–14.

    CAS  PubMed  Google Scholar 

  19. Aiach M, Gandrille S, Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost. 1995;74(1):81–9.

    CAS  PubMed  Google Scholar 

  20. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90(3):1004–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Koster T, Rosendaal FR, de Ronde H, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342(8886–8887):1503–6.

    Article  CAS  PubMed  Google Scholar 

  22. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330(8):517–22.

    Article  CAS  PubMed  Google Scholar 

  23. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–7.

    Article  CAS  PubMed  Google Scholar 

  24. Nicolaes GA, Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol. 2002;22(4):530–8.

    Article  CAS  PubMed  Google Scholar 

  25. Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002;100(2):524–30.

    Article  CAS  PubMed  Google Scholar 

  26. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost. 2010;8(3):445–53.

    Article  CAS  PubMed  Google Scholar 

  27. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133–4.

    Article  CAS  PubMed  Google Scholar 

  28. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997;89(2):397–402.

    CAS  PubMed  Google Scholar 

  29. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Staphano V, Cumming T, Arruda V, Hillarp A, Reny JL. Study Group for Pooled-Analysis in Venous Thromboembolism. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism—pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Thromb Haemost. 2001;86(3):809–16.

    CAS  PubMed  Google Scholar 

  30. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet. 2000;356(9225):182–3.

    Article  CAS  PubMed  Google Scholar 

  31. Meyer G, Emmerich J, Helley D, Arnaud E, Nicaud V, Alhenc-Gelas M, Aiach M, Fischer A, Sors H, Fiessinger JN. Factors V Leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med. 2001;110(1):12–5.

    Article  CAS  PubMed  Google Scholar 

  32. Emmerich J, Alhenc-Gelas M, Aillaud MF, Juhan-Vague I, Jude B, Garcin JM, Dreyfus M, de Moerloose P, Le Querrec A, Priollet P, Berruyer M, Vallantin X, Wolf M, Aiach M, Fiessinger JN. Clinical features in 36 patients homozygous for the ARG 506 → GLN factor V mutation. Thromb Haemost. 1997;77(4):620–3.

    CAS  PubMed  Google Scholar 

  33. Ehrenforth S, Nemes L, Mannhalter C, Rosendaal FR, Koder S, Zoghlami-Rintelen C, Scharrer I, Pabinger I. Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. J Thromb Haemost. 2004;2(3):430–6.

    Article  CAS  PubMed  Google Scholar 

  34. Lee R, Factor V. Leiden: a clinical review. Am J Med Sci. 2001;322(2):88–102.

    Article  CAS  PubMed  Google Scholar 

  35. Degen SJ, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochemistry. 1987;26(19):6165–77.

    Article  CAS  PubMed  Google Scholar 

  36. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698–703.

    CAS  PubMed  Google Scholar 

  37. Kyrle PA, Mannhalter C, Beguin S, Stümpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol. 1998;18(8):1287–91.

    Article  CAS  PubMed  Google Scholar 

  38. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79(4):706–8.

    CAS  PubMed  Google Scholar 

  39. Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C, Horellou MH, Seligsohn U. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood. 1998;92(4):1119–24.

    CAS  PubMed  Google Scholar 

  40. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost. 1999;82(5):1395–8.

    CAS  PubMed  Google Scholar 

  41. Jick H, Slone D, Westerholm B, Inman WHW, Vessey MP, Shapiro S, Lewis GP, Worcester J. Venous thromboembolic disease and ABO blood type. Lancet. 1969;1:539–42.

    Article  CAS  PubMed  Google Scholar 

  42. Morelli VM, De Visser MCH, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost. 2005;3(1):183–5.

    Article  CAS  PubMed  Google Scholar 

  43. Simioni P, Tormene D, Tognin G, Gavasso G, Iacobelli NP, Finn JD, Spieza L, Radu C, Arruda VR. X-linked thrombophilia with a mutant factor IX (Factor IX Padua). N Engl J Med. 2009;361(17):1671–5.

    Article  CAS  PubMed  Google Scholar 

  44. Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, Takagi A, Murate T, Kunishima S, Sakai M, Okamoto K, Matsushita T, Naoe T, Saito H, Kojima T. Thrombosis from a prothrombin mutation conveying antithrombotic resistance. N Engl J Med. 2012;366:2390–6.

    Article  CAS  PubMed  Google Scholar 

  45. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523–6.

    Article  PubMed  Google Scholar 

  46. Lijfering WM, Middeldorp S, Veeger NJ, Hamulyak K, Prins M, Büller HR, van der Meer J. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation. 2010;121:1706–12.

    Article  CAS  PubMed  Google Scholar 

  47. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D, Tait RC, Walker I, Watson H, British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149:209–20.

    Article  PubMed  Google Scholar 

  48. Rand JH, Wolgast LR. The antiphospholipid syndrome. Thrombophilia genetics. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White II GC, editors. Hemostasis and thrombosis. Basic principles and clinical practice. 6th ed. Philadelphia, PA: Wolters Kluwer, Lippincott Willians and Wilkins; 2013. p. 1216–31.

    Google Scholar 

  49. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.

    Article  CAS  PubMed  Google Scholar 

  50. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International concensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  CAS  PubMed  Google Scholar 

  51. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10:74–9.

    Article  PubMed  Google Scholar 

  52. Chaturvedi S, McCrae KR. Recent advances in the antiphospholipid antibody syndrome. Curr Opin Hematol. 2014;21:371–9.

    Article  CAS  PubMed  Google Scholar 

  53. Erkan D, Aguiar CL, Andrade D, et al. 14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–96.

    Article  CAS  PubMed  Google Scholar 

  54. The APASS investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576–84.

    Article  Google Scholar 

  55. Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani K, Rohmer V, Ifrah N, Belizna C. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11:1927–9.

    CAS  PubMed  Google Scholar 

  56. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176–84.

    Article  CAS  PubMed  Google Scholar 

  57. Casini A, Fontana P, Lecompte TP. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. 2013;11:1215–27.

    Article  CAS  PubMed  Google Scholar 

  58. Tefferi A. Myeloproliferative neoplasms and thrombohemorrhagic complications. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White II GC, editors. Basic principles and clinical practice. 6th ed. Philadelphia, PA: Wolters Kluwer, Lippincott Willians and Wilkins; 2013. p. 1232–43.

    Google Scholar 

  59. Levine RL. Another piece of the myeloproliferative neoplasms puzzle. N Engl J Med. 2013;369:2451–2.

    Article  CAS  PubMed  Google Scholar 

  60. Smalberg JH, Arenda LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–8.

    Article  CAS  PubMed  Google Scholar 

  61. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–33.

    Article  CAS  PubMed  Google Scholar 

  62. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. European collaboration on low-dose aspirin in polycythemia vera investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–24.

    Article  CAS  PubMed  Google Scholar 

  63. Marchioli R, Finazzi G, Specchia G, CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.

    Article  CAS  PubMed  Google Scholar 

  64. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de Médecine Vasculaire-Cardiologie, Centre de Diagnostic et de Thérapeutique—Hôtel Dieu, Université Paris Descartes, 1 rue de la Cité, 75181, Paris Cedex 04, France

    Joseph Emmerich M.D., Ph.D.

Authors
  1. Joseph Emmerich M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph Emmerich M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Dept of Surgery & Trauma Research Center, Univ of Colorado School of Medicine, Aurora, Colorado, USA

    Eduardo Gonzalez

  2. Dept of Surgery & Trauma Research Center, Univ of Colorado School of Medicine, Aurora, Colorado, USA

    Hunter B. Moore

  3. Dept of Surgery & Trauma Research Center, Univ of Colorado Sch of Med&Denver Healt, Denver, Colorado, USA

    Ernest E. Moore

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Emmerich, J. (2016). Congenital and Acquired Hypercoagulable States. In: Gonzalez, E., Moore, H., Moore, E. (eds) Trauma Induced Coagulopathy. Springer, Cham. https://doi.org/10.1007/978-3-319-28308-1_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28308-1_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-28306-7

  • Online ISBN: 978-3-319-28308-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation